Global Dicamba Intermediates Market — South Africa by Intermediate Type

Aarti Industries is India's dominant benzene-and-toluene-derivatives platform and, on the company's own account, a global top-tier producer in the nitro chloro benzene (NCB) value chain. It is not a diversified conglomerate but a deep, vertically integrated intermediates specialist: it takes commodity aromatic feedstocks — benzene, toluene, chlorine, sulphur, aniline — and converts them, through chlorination, nitration, hydrogenation, ammonolysis, ethylation, methylation and fluorination, into more than 100 downstream intermediates supplied to roughly 1,100 customers in 60 countries. Its economics are those of a cost-advantaged process manufacturer with scale barriers, not a high-margin formulator: FY2026 EBITDA margin was 14.1% and return on capital employed roughly 7%. The strategic question facing the company is whether a five-year, capital-intensive expansion cycle — Zone IV at Jhagadia, multi-purpose plants, fuel-additive capacity, and two joint ventures — converts into the ₹1,800–2,200 Cr EBITDA and >15% ROCE management has guided for FY2028, or merely into a larger, lower-returning asset base. --- ### What the company actually does Aarti Industries manufactures and sells speciality and intermediate chemicals derived principally from two aromatic feedstocks: benzene and toluene. The business is best understood not as a portfolio of products but as a set of interlocking value chains, each anchored on a core chemistry capability and extended downstream through successive reaction steps that add margin and lock in customers. The company's key disclosed value chains are: **Nitro Chloro Benzenes (NCB):** the historical core and the chain in which management claims global leadership. Products include ortho- and para-nitro chlorobenzene (ONCB/PNCB) and their downstream derivatives, feeding dyes, pigments, agrochemicals and pharmaceutical intermediates. **Di-Chloro Benzenes (DCB):** including para-dichlorobenzene (PDCB), a significant US export line, used in polymer (PPS resin) and deodorant/insecticide applications. **Phenylenediamines (PDA):** including MPDA, used in polymer additives and rubber chemicals. This chain has been the company's most persistently underperforming line, pressured by Chinese competition and soft US demand. **Nitro Toluene (NT) derivatives:** including ethylation and methylation products. Mono Methyl Aniline (MMA) — an octane-booster fuel additive — sits in this chain and has become the company's single largest volume growth engine. **Sulphuric acid and downstream:** including oleum and acid-chain derivatives; a captive-integration and merchant business. **Hydrogenation, fluorination and speciality chemistries:** cross-cutting capabilities feeding pharma and agro intermediates. ### Business model and revenue model The revenue model is almost entirely product sales of manufactured chemical intermediates. There is no subscription revenue, no software, no royalty stream of material size. Three commercial structures coexist: 1. **Spot and short-tenor merchant sales** — the majority of volume, priced against feedstock and freight, with pass-through lags of roughly one quarter. This is where margin volatility originates. 2. **Long-term supply contracts** — multi-year, volume-committed agreements with global agrochemical and chemical majors. Two are currently material: a US$150 million multi-year agrochemical intermediate contract running to 31 March 2030, signed 12 March 2026 and requiring no incremental capex; and an exclusive long-term supply agreement with a leading global chemical company, materially amended in 2026 to add a ₹200–250 Cr backward-integration investment at Dahej SEZ, converting the relationship into an end-to-end manufacturing model over a remaining 15-year term. India Ratings has cited these contracts as a core support to AIL's revenue visibility. 3. **CDMO / custom synthesis and contract manufacturing (CRAMS)** — marketed as a growth avenue, executed through the pilot plant and the new Multi-Purpose Plant (MPP) at Jhagadia. Current CDMO revenue contribution is not separately disclosed. ### Value chain position AIL sits in the middle of the chemical value chain: downstream of petrochemical crackers and chlor-alkali producers, upstream of formulators (agrochemical companies, pharmaceutical API makers, dye houses, polymer compounders, fuel blenders). This position confers two structural properties. First, the company is a price-taker on inputs and a price-setter only where it holds technical or scale monopoly — which is why crude-linked benzene and toluene inflation compresses margin before it can be passed through. Second, because switching an approved intermediate requires customer requalification, incumbency is sticky: customer qualification cycles are a moat, and the company's repeated references to "customer qualification phase" for PEDA and MPP products reflect this. ### Customer types and end-markets | End-use application | Share of revenue Q1 FY2027 (%) | |---|---| | Energy and additives (fuel additives / octane boosters) | 38 | | Agrochemicals and fertilizers | 18 | | Dyes, pigments and printing inks | 15 | | Pharmaceuticals | 14 | | Polymer and additives | 11 | | Other / unallocated (residual) | 4 | Customers are industrial B2B buyers: global agrochemical innovators, pharmaceutical and API manufacturers, dye and pigment houses, polymer and additive producers, and fuel blenders/refiners. The company reports 1,100+ customers across 60 countries, with exports at 59% of revenue in Q1 FY2027. End-market exposure (Q1 FY2027, unaudited, from investor presentation): ### The company's own characterisation vs. an independent view The company describes itself as "a leading global speciality chemicals company" with "40 years of chemistry expertise," combining "process chemistry expertise with scale-up engineering to deliver advanced intermediates." **Independent characterisation:** the "speciality" label overstates the margin structure. A genuine speciality chemicals business earns 20–30% EBITDA margins and high-teens ROCE through formulation IP and application service. Aarti earns 14% EBITDA margins and ~7% ROCE, with margins that move with benzene, toluene, freight and Chinese export pricing. What Aarti actually possesses is a scale-and-integration cost position in a set of mid-value aromatic intermediates, with genuine global scale in NCB and a genuinely differentiated position in octane-booster fuel additives. That is a valuable, defensible business — but it is closer to an integrated intermediates franchise than to a speciality formulator, and it should be valued and stress-tested accordingly.

BASF is the world's largest chemical company by sales, built on the Verbund principle of physically and energetically integrated production sites that turn a handful of feedstocks into thousands of products. Since September 2024 it has run under the "Winning Ways" strategy, which splits the portfolio into four core segments (Chemicals, Materials, Industrial Solutions, Nutrition & Care) that stay integrated, and standalone businesses (Agricultural Solutions, Battery Materials, Environmental Catalyst and Metal Solutions, and the now-divested Coatings) that are being monetized or prepared for capital-market options. In 2025 it generated €59.7 billion in sales and €6.6 billion in EBITDA before special items, a cyclical trough. In 2026 it closed the €7.7 billion Coatings transaction, started up its €-multi-billion Zhanjiang Verbund site, raised earnings guidance, and approached Evonik about a takeover. The investment debate is whether structural cost cuts and portfolio proceeds can restore returns above the cost of capital. --- **The company's own description.** BASF describes its purpose with the line "we create chemistry for a sustainable future" (BASF news release boilerplate, 2026) and states its ambition to be the preferred chemical company for enabling customers' green transformation. It reports around 108,000 employees, customers in nearly every sector and almost every country, and sales of around €60 billion in 2025. The portfolio is described as four core segments plus standalone businesses bundled in Surface Technologies and Agricultural Solutions. **Independent characterization.** BASF is best understood as three businesses under one roof: 1. **An integrated commodity and intermediates engine** (Chemicals, the Monomers half of Materials). This is a steam-cracker-to-derivatives chain selling ethylene and propylene derivatives, isocyanates, polyamide precursors and intermediates on spread economics. Earnings are driven by feedstock and energy costs, operating rates and regional supply-demand. It is the most capital-intensive part of the group and the main source of the 2023–2025 earnings decline: Chemicals EBITDA before special items fell from €1,342 million in 2024 to €853 million in 2025 (Factsheet FY2025). 2. **Formulated and performance products** (Performance Materials, Industrial Solutions, Nutrition & Care). These sell on specification and performance to automotive, construction, packaging, consumer goods, pharma and nutrition customers. Margins are steadier but have come under pressure from Asian competition and, in Care Chemicals, from consumer trading-down to private-label products (Factsheet FY2025 commentary). 3. **Standalone franchises** with different industry logic: Agricultural Solutions (crop protection, seeds and traits, digital farming), ECMS (emissions catalysts plus precious-metal trading and recycling) and Battery Materials. Agricultural Solutions is the group's highest-margin segment at 21.7% EBITDA margin before special items in FY2025 and the largest single earnings contributor at €2,081 million. **Revenue model.** Revenue is almost entirely product sales under supply contracts and spot transactions. There is no subscription model of consequence; digital farming (xarvio) and licensing of process technology and catalysts are small. Seeds and traits include royalty and licensing income within Agricultural Solutions, not separately disclosed. Precious-metal trading inflates ECMS sales (€7,978 million in FY2025) with pass-through metal value, which is why BASF quotes group margins both including and excluding metals (12.3% excluding metals in FY2025 per the CFO on the February 27, 2026 call, versus 11.0% reported). **Value chain position.** Upstream to midstream in petrochemicals with captive crackers at Ludwigshafen, Antwerp, Port Arthur (joint venture with TotalEnergies), Nanjing (joint venture with Sinopec) and Zhanjiang; midstream to downstream in engineering plastics, polyurethane systems, dispersions, additives, surfactants and vitamins; branded and channel-driven in agriculture. BASF exited upstream oil and gas operations when Wintershall Dea's E&P business was transferred to Harbour Energy in September 2024. **Customers and end-markets.** BASF serves industrial customers in chemicals and plastics, transportation, construction, consumer goods, agriculture, electronics, energy and resources, and health and nutrition. Intersegment transfers are large (Chemicals transferred €3,432 million internally in FY2025 on €10,055 million of third-party sales), which shows how much of the upstream output feeds BASF's own downstream chains.

Bayer is a German life-science group with three businesses: Crop Science, Pharmaceuticals and Consumer Health. It is the world's largest combined seed, trait and crop-protection supplier, a mid-sized prescription-drug maker, and a top-five self-care company. Fiscal 2025 sales were EUR 45.6 billion. The 2018 purchase of Monsanto brought leading corn and soybean genetics but also glyphosate and PCB litigation, which has consumed well over EUR 10 billion in settlements and produced net losses in 2023, 2024 and 2025. Under CEO Bill Anderson the company has cut management layers, held the dividend at the legal minimum, and concentrated on four priorities: rebuilding the pharma pipeline, containing litigation, reducing debt and improving crop profitability. In 2026 a 7–2 U.S. Supreme Court ruling on federal pre-emption and a proposed USD 7.25 billion class settlement moved the litigation closer to resolution, though the settlement still awaits final court approval. --- **Company's own description.** Bayer describes itself as a global enterprise with core competencies in the life-science fields of health care and nutrition, operating under the mission "Health for all, Hunger for none" (Annual Report 2025; press boilerplate 2026). Bayer AG is a holding company; operations sit in subsidiaries worldwide. In fiscal 2025 the Group had about 88,000 employees, sales of EUR 45.6 billion and R&D expenses of EUR 5.8 billion. **Independent characterisation.** Bayer is best understood as three distinct businesses sharing a balance sheet, a brand and a legal liability. Crop Science (47 percent of FY2025 sales) is an input supplier to farmers. It earns money from proprietary seed and biotech traits, from chemical and biological crop protection, and to a small extent from digital farming subscriptions. Seed and trait revenue carries royalty-like economics: Bayer licenses traits to other seed companies, and two licensing settlements with Corteva lifted results in Q4 2025 and Q1 2026. The business is strongly seasonal, with Northern Hemisphere sales concentrated in the first half and Latin American sales in the second. Pharmaceuticals (39 percent of sales) discovers, develops and sells prescription medicines, concentrated in cardiovascular and renal disease, oncology, women's health and ophthalmology, plus a radiology unit selling contrast agents and injector hardware. Revenue is almost entirely product sales, with some licence income (for example U.S. Xarelto royalties from Johnson & Johnson, and Eylea outside the United States under a collaboration with Regeneron). The division is in the middle of a patent transition: Xarelto and Eylea are declining while Nubeqa and Kerendia are growing quickly. Consumer Health (13 percent of sales) sells non-prescription brands through pharmacies, mass retail and e-commerce. It is a branded consumer-goods model with stable margins and low capital intensity. **Revenue model mix.** Bayer does not disclose a product/service/licensing split. On the evidence of the Annual Report 2025, the large majority of revenue is product sales; licensing income is embedded in Crop Science seed and trait lines and in Pharmaceuticals; subscription revenue (Climate FieldView, radiology software) is immaterial at Group level. An exact percentage split is not publicly disclosed. **Value-chain position.** Bayer is a research-based originator and manufacturer. It owns discovery, development, active-ingredient and finished-product manufacturing, and commercial organisations, and sells through distributors, retailers, wholesalers, hospitals and pharmacies rather than directly to end users in most markets. **Customers and end markets.** Farmers, agricultural retailers and distributors, and seed licensees (Crop Science); wholesalers, hospitals, physicians, pharmacy chains, governments and payers (Pharmaceuticals); pharmacies, supermarkets, drugstores and online retailers (Consumer Health).